Tech Company Financing Transactions
Amber Therapeutics Funding Round
New Enterprise Associates, 8VC and F-Prime Capital participated in a $100 million Series A funding round for Amber Therapeutics. The round closed on 6/10/2024.
Transaction Overview
Company Name
Announced On
6/10/2024
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors
New Enterprise Associates (Lead Investor) (Tiffany Le)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
242 Acklam Road
London, W10 5YG
UK
London, W10 5YG
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Amber Therapeutics was founded in 2021 by Aidan Crawley, Tim Denison, Stefan De Wachter and Charles Knowles with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation. Amber UI is the company's first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Aidan Crawley
Chief Marketing Officer
Charles Knowles
Chief Scientific Officer
Stefan De Wachter
VP - Engineering
Tim Denison
VP - Operations
Tomás Furey
VP - Regulatory Affairs
Iain Anthony
Browse more venture capital transactions:
Prev: 6/10/2024: Jump venture capital transaction
Next: 6/10/2024: Stake Properties venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs